IQVIA Holdings Inc. $IQV Shares Purchased by OVERSEA CHINESE BANKING Corp Ltd

OVERSEA CHINESE BANKING Corp Ltd boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 29.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,037 shares of the medical research company’s stock after buying an additional 2,941 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd’s holdings in IQVIA were worth $2,939,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in IQV. Claret Asset Management Corp boosted its stake in IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares during the period. Versant Capital Management Inc boosted its stake in IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. boosted its stake in IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after purchasing an additional 58 shares during the period. Brookstone Capital Management boosted its stake in IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares during the period. Finally, Private Advisor Group LLC boosted its stake in IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.2%

Shares of NYSE:IQV opened at $175.34 on Thursday. The firm has a fifty day moving average of $170.28 and a two-hundred day moving average of $203.30. The firm has a market capitalization of $29.76 billion, a P/E ratio of 22.31, a price-to-earnings-growth ratio of 1.75 and a beta of 1.39. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on IQV shares. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Citigroup decreased their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Truist Financial decreased their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Finally, Evercore reissued an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Buy” and a consensus price target of $226.63.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.